Information Provided By:
Fly News Breaks for November 25, 2019
Nov 25, 2019 | 06:57 EDT
Cantor Fitzgerald analyst Eliana Merle raised her price target for Apellis Pharmaceuticals to $54 from $50 and reiterates an Overweight rating on the shares. The analyst thinks the upcoming Phase 3 Pegasus data could be a key clinical de-risking for APL-2 C3 platform in paroxysmal nocturnal hemoglobinuria and beyond. Merle sees "significant optionality" over 2020-2021 across many of Apellis' programs.
News For APLS From the Last 2 Days
There are no results for your query APLS